“Biogen Idec (BIIB) has been reiterated by TheStreet Ratings as a buy with a ratings score of A . The company’s strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”
,” TheStreet’s analyst commented.
Several other analysts have also recently commented on the stock. Analysts at Morgan Stanley raised their price target on shares of Biogen Idec from $170.00 to $177.00 in a research note to investors on Monday. Finally, analysts at Bank of America raised their EPS on shares of Biogen Idec in a research note to investors on Thursday, February 28th. They now have a neutral rating and a $177.00 price target on the stock.
Fifteen investment analysts have rated the stock with a buy rating, one has assigned an overweight rating, and fourteen have assigned a hold rating to the company’s stock. The company has an average rating of overweight and a consensus price target of $175.74.
Biogen Idec (NASDAQ: BIIB) traded up 0.43% on Tuesday, hitting $176.90. Biogen Idec has a 1-year low of $118.52 and a 1-year high of $176.47. The stock’s 50-day moving average is currently $162.9. The company has a market cap of $41.804 billion and a price-to-earnings ratio of 30.58.
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.